


## Research Article




**Fig. 5. Decision tree for the prediction of response to therapy.** The boxes indicate the factors used for splitting. Pie charts indicate the rate of response for each group of patients after splitting. The rate of null virological response, relapse, and sustained virological response is shown. [This figure appears in colour on the web.]

group of patients. Using this model, we can rapidly develop an estimate of the response before treatment, by simply allocating patients to subgroups by following the flow-chart form, which may facilitate clinical decision making. This is in contrast to the calculating formula, which was constructed by the traditional logistic regression model. This was not widely used in clinical practice as it is abstruse and inconvenient. These results support the evidence based approach of selecting the optimum treatment strategy for individual patients, such as treating patients with a low probability of NVR with current PEG-IFN/RBV combination therapy or advising those with a high probability of NVR to wait for more effective future therapies. Patients with a high probability of relapse may be treated for a longer duration to avoid a relapse. Decisions may be based on the possibility of a response against a potential risk of adverse events and the cost of the therapy, or disease progression while waiting for future therapy.

We have previously reported the predictive model of early virological response to PEG-IFN and RBV in chronic hepatitis C

[26]. The top factor selected as significant was the grade of steatosis, followed by serum level of LDL cholesterol, age, GGT, and blood sugar. The mechanism of association between these factors and treatment response was not clear at that time. To our interest, a recent study by Li et al. [47] has shown that high serum level of LDL cholesterol was linked to the IL28B major allele (CC in rs12979860). High serum level of LDL cholesterol was associated with SVR but it was no longer significant when analyzed together with the IL28B genotype in multivariate analysis. Thus, the association between treatment response and LDL cholesterol levels may reflect the underlining link of LDL cholesterol levels to IL28B genotype. Steatosis is reported to be correlated with low lipid levels [48] which suggest that IL28B genotypes may be also associated with steatosis. In fact, there were significant correlations between the IL28B genotype and the presence of steatosis in the present study (Table 4). In addition, the serum level of GGT, another predictive factor in our previous study, was significantly associated with IL28B genotype in the present study

## JOURNAL OF HEPATOLOGY



**Fig. 6. Validation of the CART analysis.** Each patient in the validation group was allocated to one of the six subgroups by following the flow-chart form of the decision tree. The rate of (A) sustained virological response (SVR) and (B) null virological response (NVR) in each subgroup was calculated and plotted. The X-axis represents the rate of SVR or NVR in the model building patients and the Y-axis represents those in the validation patients. The rate of SVR and NVR in each subgroup of patients is closely correlated between the model building and the validation patients (correlation coefficient:  $r^2 = 0.98-0.99$ ).

(Table 4). The serum level of GGT was significantly associated with NVR when examined independently but was no longer significant when analyzed together with the IL28B genotype. These observations indicate that some of the factors that we have previously identified may be associated with virological response to therapy through the underlining link to the IL28B genotype.

In conclusion, the present study highlighted the impact of the IL28B polymorphism and mutation in the ISDR on the pre-treatment prediction of response to PEG-IFN/RBV therapy. A decision model including these host and viral factors has the potential to

support selection of the optimum treatment strategy for individual patients, which may enable personalized treatment.

#### Conflicts of interest

The authors who have taken part in this study declare that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

#### Financial support

This study was supported by a grant-in-aid from the Ministry of Health, Labor and Welfare, Japan, (H19-kannen-013), (H20-kannen-006).

#### References

- Ray Kim W. Global epidemiology and burden of hepatitis C. *Microbes Infect* 2002;4 (12):1219-1225.
- Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncalves Jr FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002;347 (13):975-982.
- Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001;358 (9286):958-965.
- Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. *Intervirology* 2005;48 (6):372-380.
- Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. *Hepatology* 2003;38 (3):645-652.
- Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. *Nat Genet* 2009;41:1105-1109.
- Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. *Nat Genet* 2009;41:1100-1104.
- Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. *Nature* 2009;461 (7262):399-401.
- Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. *Gastroenterology* 2010;138 (4):1338-1345.
- Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NSSA region. *J Clin Invest* 1995;96 (1):224-230.
- Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. *N Engl J Med* 1996;334 (2):77-81.
- Kurosaki M, Enomoto N, Murakami T, Sakuma I, Asahina Y, Yamamoto C, et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NSSA region of hepatitis C virus in relation to the response to interferon-beta therapy. *Hepatology* 1997;25 (3):750-753.
- Shirakawa H, Matsumoto A, Joshita S, Komatsu M, Tanaka N, Umemura T, et al. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. *Hepatology* 2008;48 (6):1753-1760.
- Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. *J Hepatol* 2007;46 (3):403-410.

## Research Article

- [15] Okanoue T, Itoh Y, Hashimoto H, Yasui K, Minami M, Takehara T, et al. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. *J Gastroenterol* 2009;44 (9):952-963.
- [16] Segal MR, Bloch DA. A comparison of estimated proportional hazards models and regression trees. *Stat Med* 1989;8 (5):539-550.
- [17] LeBlanc M, Crowley J. A review of tree-based prognostic models. *Cancer Treat Res* 1995;75:113-124.
- [18] Garzotto M, Beer TM, Hudson RG, Peters L, Hsieh YC, Barrera E, et al. Improved detection of prostate cancer using classification and regression tree analysis. *J Clin Oncol* 2005;23 (19):4322-4329.
- [19] Averbook BJ, Fu P, Rao JS, Mansour EG. A long-term analysis of 1018 patients with melanoma by classic Cox regression and tree-structured survival analysis at a major referral center: implications on the future of cancer staging. *Surgery* 2002;132 (4):589-602.
- [20] Leiter U, Buettner PG, Eigentler TK, Garbe C. Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the german dermatological society. *J Clin Oncol* 2004;22 (18):3660-3667.
- [21] Valera VA, Walter BA, Yokoyama N, Koyama Y, Iiai T, Okamoto H, et al. Prognostic groups in colorectal carcinoma patients based on tumor cell proliferation and classification and regression tree (CART) survival analysis. *Ann Surg Oncol* 2007;14 (1):34-40.
- [22] Zlobec I, Steele R, Nigam N, Compton CC. A predictive model of rectal tumor response to preoperative radiotherapy using classification and regression tree methods. *Clin Cancer Res* 2005;11 (15):5440-5443.
- [23] Thabane M, Simunovic M, Akhtar-Danesh N, Marshall JK. Development and validation of a risk score for post-infectious irritable bowel syndrome. *Am J Gastroenterol* 2009;104 (9):2267-2274.
- [24] Wu BU, Johannes RS, Sun X, Tabak Y, Conwell DL, Banks PA. The early prediction of mortality in acute pancreatitis: a large population-based study. *Gut* 2008;57 (12):1698-1703.
- [25] Fonarow GC, Adams Jr KF, Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. *Jama* 2005;293 (5):572-580.
- [26] Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, et al. A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. *Hepatol Res* 2010;40 (3):251-260.
- [27] Nishida N, Tanabe T, Takasu M, Suyama A, Tokunaga K. Further development of multiplex single nucleotide polymorphism typing method, the DigiTag2 assay. *Anal Biochem* 2007;364 (1):78-85.
- [28] Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goester T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. *N Engl J Med* 2009;360 (18):1839-1850.
- [29] McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. *N Engl J Med* 2009;360 (18):1827-1838.
- [30] Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. *Gastroenterology* 2009;136 (3):856-862.
- [31] Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. *Gastroenterology* 2006;131 (6):1887-1898.
- [32] Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. *J Virol* 2005;79 (6):3851-3854.
- [33] McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, et al. Replicated association between an IL28B Gene Variant and a Sustained Response to Pegylated Interferon and Ribavirin. *Gastroenterology* 2010;138:2307-2314.
- [34] Tanaka Y, Nishida N, Sugiyama M, Tokunaga K, Mizokami M.  $\Lambda$ -interferons and the single nucleotide polymorphisms: a milestone to tailor-made therapy for chronic hepatitis C. *Hepatol Res* 2010;40:449-460.
- [35] Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. *Hepatology* 2007;46 (1):37-47.
- [36] Mori N, Imamura M, Kawakami Y, Saneto H, Kawaoka T, Takaki S, et al. Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy. *J Med Virol* 2009;81 (4):640-649.
- [37] Hung CH, Lee CM, Lu SN, Lee JF, Wang JH, Tung HD, et al. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin. *J Viral Hepat* 2003;10 (2):87-94.
- [38] Yen YH, Hung CH, Hu TH, Chen CH, Wu CM, Wang JH, et al. Mutations in the interferon sensitivity-determining region (nonstructural 5A amino acid 2209-2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin. *Aliment Pharmacol Ther* 2008;27 (1):72-79.
- [39] Zeuzem S, Lee JH, Roth WK. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. *Hepatology* 1997;25 (3):740-744.
- [40] Squadrito G, Leone F, Sartori M, Nalpas B, Berthelot P, Raimondo G, et al. Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. *Gastroenterology* 1997;113 (2):567-572.
- [41] Sarrazin C, Berg T, Lee JH, Teuber G, Dietrich CF, Roth WK, et al. Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy. *J Hepatol* 1999;30 (6):1004-1013.
- [42] Murphy MD, Rosen HR, Marousek GI, Chou S. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection. *Dig Dis Sci* 2002;47 (6):1195-1205.
- [43] Pascu M, Martus P, Hohne M, Wiedenmann B, Hopf U, Schreier E, et al. Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. *Gut* 2004;53 (9):1345-1351.
- [44] Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huiginn C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. *Nature* 2009;461 (7265):798-801.
- [45] Kurosaki M, Enomoto N, Marumo F, Sato C. Evolution and selection of hepatitis C virus variants in patients with chronic hepatitis C. *Virology* 1994;205 (1):161-169.
- [46] Enomoto N, Kurosaki M, Tanaka Y, Marumo F, Sato C. Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis. *J Gen Virol* 1994;75 (Pt 6):1361-1369.
- [47] Li JH, Lao XQ, Tillmann HL, Rowell J, Patel K, Thompson A, et al. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. *Hepatology* 1904;51 (6):1904-1911.
- [48] Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. *J Hepatol* 2001;34 (3):428-434.

# Effect of Aging on Risk for Hepatocellular Carcinoma in Chronic Hepatitis C Virus Infection

Yasuhiro Asahina,<sup>1</sup> Kaoru Tsuchiya,<sup>1</sup> Nobuharu Tamaki,<sup>1</sup> Itsuko Hirayama,<sup>1</sup> Tomohiro Tanaka,<sup>1</sup> Mitsuaki Sato,<sup>1,2</sup> Yutaka Yasui,<sup>1</sup> Takanori Hosokawa,<sup>1</sup> Ken Ueda,<sup>1</sup> Teiji Kuzuya,<sup>1</sup> Hiroyuki Nakanishi,<sup>1</sup> Jun Itakura,<sup>1</sup> Yuka Takahashi,<sup>1</sup> Masayuki Kurosaki,<sup>1</sup> Nobuyuki Enomoto,<sup>2</sup> and Namiki Izumi<sup>1</sup>

**An increase in the aging population is an impending problem. A large cohort study was carried out to determine the influence of aging and other factors on hepatocarcinogenesis in patients treated with interferon. Biopsy-proven 2547 chronic hepatitis C patients registered at our referral center since 1992 were included. Of these, 2166 were treated with interferon-based therapy. Incidences of hepatocellular carcinoma (HCC) associated with interferon were analyzed by Kaplan-Meier and person-years methods for an average follow-up of 7.5 years. Factors associated with HCC risk were determined by Cox proportional hazard analysis. HCC developed in 177 interferon-treated patients. The risk for HCC depended on age at primary biopsy and increased more than 15-fold after 65 years of age. Even when stratified by stage of fibrosis, the cumulative and annual incidences of HCC were significantly higher in older patients than in younger patients ( $P < 0.001$ ) at the same stage of fibrosis, except for cirrhosis. Progression of fibrosis over time was significantly accelerated in older patients. The impact of viral eradication on HCC prevention was less significant in older patients than in younger patients. Multivariate analysis confirmed that age, gender, liver fibrosis, liver steatosis, total cholesterol level, fasting blood sugar level, baseline and postinterferon alpha-fetoprotein level, and virological response to interferon were independent risk factors associated with HCC. Aging was the strongest risk factor for a nonvirological response to interferon-based antiviral therapy. *Conclusion:* Elderly patients are at a higher risk for HCC. Hepatitis C viral eradication had a smaller effect on hepatocarcinogenesis in older patients. Patients should therefore be identified at an earlier age and treatment should be initiated. (HEPATOLOGY 2010;52:518-527)**

Primary liver cancer is the third most common cause of cancer mortality worldwide,<sup>1</sup> and hepatocellular carcinoma (HCC) is one of the most frequent primary liver cancers.<sup>2,3</sup> Infection with hepatitis C virus (HCV) is a common cause of chronic hepatitis, which progresses to HCC in many patients.<sup>4</sup> The prevalence of older patients has been increasing in

Japan, and this is an impending problem in other countries where viral spread has occurred more recently.<sup>5</sup> The number of Americans older than 65 years is expected to double by the year 2030.<sup>6</sup> In Western Europe, people older than 65 years already constitute 15%-18% of the population<sup>7</sup>; thus, aging patient who is chronically infected with HCV is

Abbreviations: AFP, alpha-fetoprotein; HBe, hepatitis B core; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; NASH, nonalcoholic steatohepatitis; SVR, sustained virological response.

From the <sup>1</sup>Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan; and <sup>2</sup>First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.

Received December 4, 2009; accepted March 15, 2010.

Supported by grants from the Japanese Ministry of Education, Culture, Sports, Science, and Technology, and the Japanese Ministry of Welfare, Health, and Labor.

Address reprint requests to: Namiki Izumi, M.D., Ph.D., Chief, Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo 180-8610, Japan. E-mail: nizumi@musashino.jrc.or.jp; fax: +81-422-32-9551.

Copyright © 2010 by the American Association for the Study of Liver Diseases.

Published online in Wiley InterScience (www.interscience.wiley.com).

DOI 10.1002/hep.23691

Potential conflict of interest: Nothing to report.

Additional Supporting Information may be found in the online version of this article.

one of the most important issues confronted by physicians.

Viral eradication with interferon-based therapy for chronic hepatitis C has been shown to prevent HCC by studies conducted in Japan and Italy.<sup>8-11</sup> However, this finding is controversial according to another study conducted in Europe and Canada,<sup>12</sup> in which viral eradication did not significantly reduce the risk for HCC in 479 consecutively treated patients. The likelihood of development of HCC among interferon-treated patients is difficult to determine because of the paucity of adequate long-term cohort studies. Moreover, in patients who are treated with interferon the effect of certain factors, including aging, on the risk for HCC remains unclear. Furthermore, the benefit of viral eradication with interferon-based therapy, including pegylated interferon and ribavirin combination therapy, in older patients remains unknown. To further clarify this, we conducted a large-scale, long-term cohort study and analyzed the influence of aging and other host and virological factors in patients treated with interferon.

## Patients and Methods

**Patients.** Consecutive patients (n = 2547) chronically infected with HCV who underwent liver biopsy between 1992 and January 2008 at our referral center were enrolled. Of these, 2166 patients were treated with interferon-based antiviral therapy, whereas 381 patients did not receive interferon treatment (Fig. 1). All patients had histologically proven chronic hepatitis or cirrhosis. HCV infection was proven in all patients by identification of HCV RNA. Patients with a history of HCC, autoimmune hepatitis, or primary biliary cirrhosis were excluded. We also excluded patients who had a history of excessive alcohol consumption (50 g/day) and confirmed alcohol abstinence during follow-up. No patient was positive for hepatitis B surface antigen or antihuman immunodeficiency virus antibody. Written informed consent was obtained from all patients. The study was approved by the Ethical Committee of Musashino Red Cross Hospital in accordance with the Declaration of Helsinki.

**Histological Evaluation.** A liver biopsy specimen was obtained laparoscopically using 13G needles. When laparoscopy was impossible, ultrasound-guided liver biopsy was performed with 15G needles (n = 254). The mean length of the specimen was 18 mm (range 12-40 mm), and the mean number of portal tracts was 17 (range 8-34). Liver biopsy specimens




Fig. 1. Clinical outcomes of the patients enrolled in the present study. HCC, hepatocellular carcinoma; SVR, sustained virological response.

were scored by board-certified pathologists for stage of fibrosis and grade of inflammatory activity according to the classification of Desmet et al.<sup>13</sup> Additional macroscopic pathological information was obtained from laparoscopic findings. The percentage of steatosis was quantified by determining the average proportion of hepatocytes affected by steatosis. In this study, superimposed nonalcoholic steatohepatitis (NASH) was defined as a central pattern of colocalization of hepatic steatosis and hepatocyte ballooning with pericellular/perisinusoidal fibrosis or Mallory hyaline.

**Interferon Treatment.** Among the 2166 patients treated with interferon-based antiviral therapy, 1062 patients received interferon-alpha or beta monotherapy either for 24 weeks (n = 1003) or for 2 to 5 years (n = 59); 386 patients received interferon-alpha and ribavirin combination therapy for 24 weeks; 306 received pegylated interferon-alpha monotherapy for 48 weeks; and 412 received pegylated interferon-alpha and ribavirin combination therapy for 48 weeks. All interferon treatment was initiated within 48 weeks after liver biopsy.

**Definitions of Response to Interferon Therapy.** A patient negative for serum HCV RNA after the first 6 months of completion of interferon-based therapy was defined as a sustained viral responder. HCV RNA was determined by the qualitative Amplicor or TaqMan HCV assay (Roche Molecular Diagnostics, Tokyo, Japan).

**Data Collection and Patient Follow-up.** Data on patient characteristics, biochemical data, hematological

data, virological data, histological data, and treatment details were collected at enrollment. Age was determined at primary liver biopsy. Patients were examined for HCC with abdominal ultrasonography, dynamic computed tomography, and/or magnetic resonance imaging every 3-6 months. Serum alpha-fetoprotein (AFP) levels were measured every 1-2 months. This screening program constitutes the standard of care in Japan. To evaluate the effect of interferon-induced AFP reduction on hepatocarcinogenesis, the average AFP level after interferon treatment was calculated in each patient. HCC diagnosis was confirmed with needle biopsy, surgically resected specimens, or typical radiological findings diagnosed by board-certified radiologists. Figure 1 shows the schema for patient follow-up and clinical outcomes.

The start date of follow-up was the date of primary liver biopsy and the endpoint of follow-up was the development of HCC or the latest medical attendance until January 2009. The mean follow-up period was 7.5 years (range 0.5-17 years). The factors associated with development of HCC were retrospectively analyzed.

**Change in Fibrosis Staging Over Time.** To evaluate change in fibrosis staging over time, 271 patients who had not achieved a sustained virological response (SVR) with interferon therapy underwent a sequential biopsy after the initial biopsy. The interval between the paired biopsies was on average 4.8 years (range 0.7-14 years). The yearly rate of progression of fibrosis was calculated as the change in fibrosis staging divided by the time between paired biopsies.

**Statistical Analysis.** Categorical data were compared by the chi-square test and Fisher's exact test. Distributions of continuous variables were analyzed with Student's *t* test or the Mann-Whitney *U* test for two groups. All tests of significance were two-tailed and a *P* value of <0.05 was considered statistically significant. The cumulative incidence curve was determined with the Kaplan-Meier method and differences among groups were assessed using the log-rank test. Factors associated with HCC risk and virological response to interferon therapy were determined by the Cox proportional hazard model and logistic regression analysis, respectively. To depict the role of aging in developing risk for HCC, the multivariate Cox proportional hazard model was used after adjusting for stage of liver fibrosis, steatosis, and virological response to interferon. A polynomial regression was used to fit risk ratios for segments of the age distribution. Statistical analyses were performed using the Statistical Package for the Social Sciences software version 11.0 (SPSS, Chicago, IL).

## Results

**Patient Characteristics.** Patient characteristics at the time of enrollment are shown in Table 1. The distribution of stages of liver fibrosis differed between younger and older patients, indicating the need to adjust for stage of liver fibrosis when comparing the two subgroups.

**Response to Interferon Therapy.** The response to interferon therapy was determined in 2042 (97.2%) of the interferon-treated patients, excluding those who received prolonged interferon treatment at the endpoint. SVR rates are shown in Table 1. The percentage of patients showing SVR was significantly lower in older patients ( $\geq 65$  years) than in younger patients (<65 years) ( $P < 0.001$ ). Overall response rates to the different types of interferon therapy were as follows: interferon monotherapy, 31.5% (312/992); interferon-alpha and ribavirin combination therapy, 28.6% (108/378); pegylated interferon-alpha monotherapy, 37.9% (108/285); and pegylated interferon-alpha and ribavirin combination therapy, 41.1% (159/387). Response rates in genotype-1 patients ( $n = 1347$ ) were 20.6% (114/554), 17.9% (29/162), 18.9% (56/297), and 36.8% (123/334), and those in nongenotype-1 patients ( $n = 565$ ) were 52.2% (163/312), 63.1% (77/122), 65.0% (52/80), and 70.6% (36/51). Overall response rates of interferon and pegylated interferon monotherapy seem to be high because of the high response rates in the nongenotype-1 patients treated with these regimens.

**Overall Cumulative Incidence of HCC.** During follow-up, HCC developed in 177 interferon-treated patients (Fig. 1). The cumulative incidence of HCC 5, 10, and 15 years after interferon therapy was 4.7%, 11.6%, and 15.5%, respectively. The cumulative incidence in SVR patients was 2.1%, 4.3%, and 4.3%, respectively, which was significantly lower than that in non-SVR patients (5.8%, 14.9%, and 20.2%, respectively; log-rank test,  $P < 0.001$ ).

**Effect of Aging on Risk for HCC.** The risk ratio determined by multivariate Cox proportional hazards analysis after adjustment for stage of liver fibrosis, degree of liver steatosis, and virological response to interferon demonstrated that the risk for HCC after interferon treatment was age-dependent and increased predominantly when the age at primary liver biopsy was  $>65$  years (Fig. 2A). Hence, we defined older patients as those  $\geq 65$  years of age at primary liver biopsy and younger patients as those aged  $<65$  years. As shown in Fig. 2B, the cumulative incidence of HCC was significantly higher in older patients than in younger patients (log-rank test,  $P < 0.001$ ).

**Table 1. Characteristics of Patients Enrolled in the Present Study**

Characteristics	Total	<65 year	≥65 year	P Value*
Patients, n	2166	1614	552	
Sex, n (%)				<0.001†
Male	1080 (49.9)	840 (52.0)	240 (43.6)	
Female	1086 (50.1)	774 (48.0)	312 (56.4)	
Age (SD), year	55.4 (12.1)	51.1 (10.8)	68.4 (2.9)	<0.001‡
BMI (SD), kg/m <sup>2</sup>	23.3 (3.1)	23.4 (3.0)	23.3 (3.1)	0.9‡
Fibrosis stage, n (%)				<0.001†
F0	27 (1.3)	24 (1.5)	3 (0.5)	
F1	860 (39.7)	704 (43.6)	156 (28.2)	
F2	733 (33.8)	515 (31.9)	218 (39.5)	
F3	444 (20.5)	301 (18.6)	143 (25.9)	
F4	102 (4.7)	70 (4.3)	32 (5.8)	
%Severe steatosis (≥10%)	27.6	27.1	29.3	0.4†
ALT level (SD), IU/L	95 (18)	101 (119)	76 (58)	<0.001‡
HCV load (SD), KU/mL	880 (1046)	861 (1016)	924 (1116)	0.2‡
HCV genotype, n (%)				<0.001†
1a	7 (0.3)	5 (0.3)	2 (0.4)	
1b	1414 (69.6)	1036 (68.9)	378 (71.3)	
2a	373 (18.3)	273 (18.2)	100 (18.9)	
2b	211 (10.4)	164 (10.9)	47 (8.9)	
Others	28 (1.4)	25 (1.7)	3 (0.6)	
Duration (SD), year	7.5 (4.4)	8.1 (4.4)	5.8 (3.7)	<0.001‡
IFN regimen, n (%)				<0.001†
IFN mono	1062 (49.0)	833 (51.6)	229 (41.5)	
PEG-IFN mono	306 (14.1)	200 (12.4)	106 (19.2)	
IFN + RBV	386 (17.8)	291 (18.0)	95 (17.2)	
PEG-IFN + RBV	412 (19.0)	290 (18.0)	122 (22.1)	
SVR, n (%)	686 (33.6)§	565 (36.6)¶	121 (24.3)¶	<0.001‡

Unless otherwise indicated, data are given as the mean (SD).

ALT, alanine aminotransferase; BMI, body mass index; HCV, hepatitis C virus; IFN, interferon; N/A, not applicable; PEG, pegylated; RBV, ribavirin; SVR, sustained virological response.

\*Comparison between <65 years and ≥65 years.

†Chi-squared test.

‡Student t test.

§Virological responses were determined in 2042 patients.

¶Virological responses were determined in 1545 patients.

¶¶Virological responses were determined in 497 patients.

As shown in Fig. 2C-E, even when stratified by stage of fibrosis the cumulative incidences among patients at stages F0/F1, F2, and F3 were significantly greater in older patients than in younger patients (log-rank test,  $P < 0.001$ ). These differences were not significant among patients with cirrhosis (Fig. 2F, log-rank test,  $P = 0.7$ ).

The annual incidence of HCC after interferon treatment was calculated by the person-years method (Table 2); it increased with the degree of liver fibrosis from 0.2% (F0 or F1) to 4.6% (F4) and was higher among older patients at the same stage of liver fibrosis.

Among the 177 patients with HCC, 92 showed evidence of a single blood transfusion. We analyzed the relationship between duration of infection and age in these 92 patients. A significant and strong negative correlation was found between the interval from blood transfusion to development of HCC and the age of the patients at the time of blood transfusion ( $r =$

$-0.74$ ,  $P < 0.001$ ) (Fig. 3A). The mean duration of chronic infection was 22.0 years in patients who had received blood transfusion at >40 years of age, which was significantly shorter than that in patients who received it at ≤40 years of age (40.6 years,  $P < 0.001$ ).

The presence of cirrhosis at the time of development of HCC, which was defined as having any of the following criteria, was evaluated: (1) histological evidence for cirrhosis, (2) findings of cirrhosis in any radiological study, or (3) presence of marked portal hypertension (i.e., presence of esophagogastric varices). Following this, 142 of the 177 with HCC (80.2%) were diagnosed as having cirrhosis, of which 42 were diagnosed histologically, 69 radiologically, and 31 based on the presence of marked portal hypertension. No significant difference was found in the proportion of patients with cirrhosis between older and younger patients, at the rate of 78.3% (94/120) in older




Fig. 2. Effect of aging on the risk for HCC. (A) Risk ratio (solid line) and 95% CI (dotted lines) for the risk of HCC according to age. To show the age-dependent relationship, a multivariate Cox proportional hazard model was used after adjustment for gender, stage of liver fibrosis, body mass index, and virological response to interferon therapy. Curves were fitted using polynomial regression. (B-F) Cumulative incidence of HCC after interferon therapy among younger (<65 years, n = 552, dotted line) and older patients (≥65 years, n = 1614, solid line). (B) Overall data, P < 0.001. (C) Patients with stage F0 or F1 liver fibrosis (no or mild fibrosis with portal expansion), P < 0.001. (D) Patients with stage F2 liver fibrosis (bridging fibrosis without architectural distortion), P < 0.001. (E) Patients with stage F3 liver fibrosis (bridging fibrosis with architectural distortion), P < 0.001. (F) Patients with stage F4 liver fibrosis (cirrhosis), P = 0.7. All P values were obtained by the log-rank test. The numbers of HCC events and patients at risk at each timepoint are shown below the graphs.

patients and 84.2% (48/57) in younger patients (P = 0.36, comparison at the age of HCC development).

**Influence of Aging on Progression in Fibrosis Staging Over Time.** In 271 patients who underwent paired biopsies, fibrosis staging progressed in 69 patients (25.5%), remained unchanged in 154 (56.8%), and regressed in 48 patients (17.7%). The overall rate of progression of fibrosis in these patients was 0.06 ± 0.02 fibrosis stages per year. Progression of fibrosis over time was significantly accelerated in older patients than in younger patients (0.21 ± 0.10 versus 0.03 ± 0.21 fibrosis stages per year, P = 0.03, Mann-Whitney U test) (Fig. 3B).

**Effect of Viral Eradication on Risk for HCC in Older Patients.** As shown in Fig. 4, the effect of viral eradication on the prevention of HCC was less significant in older patients than in younger patients. The annual incidence was higher among older patients than among younger patients with the same virological response (Table 2).

**Influence of Liver Steatosis on Risk for HCC.** The cumulative incidence of HCC after interferon therapy was significantly higher in patients with severe steatosis (≥10%) than in those with milder steatosis (at 5, 10, and 15 years: 8.6%, 19.1%, 32.0% versus 1.8%, 4.8%, 7.0%, respectively, log-rank test, P < 0.001).



**Table 2. Annual Incidence of HCC After IFN Treatment**

Factors	Total	<65 Years	≥65 Years
<b>Fibrosis stage</b>			
F0/F1	0.2%	0.1%	0.9%
F2	0.8%	0.6%	1.7%
F3	2.5%	1.8%	4.6%
F4	4.6%	4.4%	5.1%
Total	1.1%	0.8%	2.4%
<b>Degree of liver steatosis</b>			
<10%	0.5%	0.2%	1.4%
≥10%	2.0%	1.8%	3.0%
<b>Virological response</b>			
SVR	0.4%	0.2%	1.3%
Non-SVR	1.4%	1.0%	2.9%

Data were calculated by the person-years method. IFN, interferon; SVR, sustained virological response.

The annual incidence was higher in older patients than in younger patients with the same degree of liver steatosis (Table 2). In patients with severe steatosis (≥10%), superimposed NASH was diagnosed in 6.0% (26/435). Overall, superimposed NASH was significantly associated with hepatocarcinogenesis on univariate analysis (risk ratio, 4.1; 95% confidence interval [CI], 1.8-9.4;  $P < 0.001$ ), but not on multivariate analysis. Superimposed NASH was significantly associated with high body mass index ( $27.2 \pm 4.6 \text{ kg/m}^2$  versus  $23.0 \pm 3.1 \text{ kg/m}^2$ ,  $P < 0.001$ ), hyperglycemia ( $186 \pm 67 \text{ mg/dL}$  versus  $115 \pm 39 \text{ mg/dL}$ ,  $P < 0.001$ ), and advanced fibrosis (F3) (risk ratio, 2.9; 95% CI, 1.4-6.0;  $P = 0.005$ ).

**Factors Associated with Hepatocarcinogenesis After Interferon Therapy.** Univariate analysis demonstrated factors that increase the risk ratio for the development of HCC (Table 3). Multivariate analysis using Cox proportional hazards regression confirmed that aging was one of the most significant independent factors associated with the development of HCC after interferon therapy. In this analysis, advanced fibrosis, presence of steatosis, male gender, lower total cholesterol level, higher fasting blood sugar level, higher baseline AFP level, insignificant improvement of mean AFP level after interferon therapy, and nonresponse to interferon therapy were also significantly associated with risk for HCC (Table 3).

We identified 22 patients in whom HCC developed even after achieving SVR. Univariate and multivariate logistic regression analyses indicated that both liver steatosis and aging were independently associated with the development of HCC among patients who achieved SVR ( $n = 686$ ) (Table 4). Anti-HBc was detected in only 4 out of 22 patients and the age distribution was similar among anti-HBc-positive and anti-HBc-negative patients.

**Response to Interferon Therapy in Older Patients.** Multivariate logistic regression analysis confirmed that aging, female gender, severe liver fibrosis, extremely severe liver steatosis, genotype-1, high HCV load, and nonuse of pegylated interferon and ribavirin were independent risk factors for non-SVR (Supporting Table 1). The odds ratio, determined by multivariate logistic regression analysis after adjustment for these factors, demonstrated that the risk for non-SVR was age-dependent (Supporting Fig. 1). It was also  $\approx 2.5$  times higher in patients aged  $\geq 65$  years than in those aged  $< 35$  years.

In patients with genotype-1b and a high viral load who were treated with pegylated interferon and ribavirin combination therapy, the SVR rate was significantly lower in older patients than in younger patients ( $< 49$  years, 59.3%; 50-59 years, 50.5%; 60-65 years, 27.3%;  $\geq 65$  years, 25.2%; intention-to-treat analysis). Multivariate logistic regression analysis showed that




Fig. 3. (A) Relationship between the interval from blood transfusion to development of HCC and the age at blood transfusion ( $n = 92$ ). A significant and strong negative correlation was observed ( $r = -0.74$ ,  $P < 0.001$ ). (B) Change in fibrosis staging over time. A total of 271 patients who had not achieved SVR by interferon therapy underwent a sequential biopsy after the initial biopsy. The yearly rate of progression of fibrosis was calculated as the change in fibrosis stage divided by the time between the paired biopsies. The yearly rate of progression of fibrosis was significantly higher in older patients ( $\geq 65$  years) than in younger patients ( $< 65$  years) ( $P = 0.03$ , Mann-Whitney  $U$  test).




Fig. 4. Cumulative incidence of HCC after interferon therapy among SVRs (dotted lines) and non-SVRs (solid lines) according to age. (A) Younger patients (<65 years). The cumulative incidence of HCC was significantly higher in SVR than in non-SVR (log-rank test,  $P < 0.001$ ). (B) Older patients ( $\geq 65$  years). The cumulative incidence of HCC was significantly higher in SVR than in non-SVR (log-rank test,  $P = 0.02$ ). However, the difference between SVR and non-SVR was less in older patients than in younger patients. The number of HCC events and patients at risk at each timepoint are shown below the graphs.

aging was the strongest independent factor contributing to SVR in these patients (data not shown). The odds ratio for the risk of non-SVR was 1.8 for each additional 10 years of age (95% CI, 1.5-2.3,  $P < 0.001$ ).

## Discussion

In this large cohort study we demonstrated that aging is significantly associated with the development of HCC in patients treated with interferon. The risk ratio increased predominantly in patients older than 65 years, which was more than 15 times that in patients in their 20s. Aging is becoming the most critical risk factor for the development of HCC. Although liver fibrosis was also an important risk factor, we clearly demonstrated that the risk for hepatocarcinogenesis after interferon treatment was significantly higher in older patients at each stage of liver fibrosis except for cirrhosis. Hence, physicians should be aware that older patients can develop HCC regardless of the stage of fibrosis.

Because the present study included a large cohort, it was difficult to determine the duration of infection in all patients, and this might have affected the risk determination for HCC development. Therefore, we analyzed the relationship between duration of chronic infection and HCC development in patients who underwent a single blood transfusion. We found a significant and strong negative correlation between the

interval from blood transfusion to development of HCC and the age of the patients at the time of blood transfusion. Consistent with our results, a previous report with posttransfusion HCV demonstrated that the age of patients, rather than the duration of HCV infection, was more significant for HCC development.<sup>14-16</sup> Therefore, older age and not duration of infection is more likely to influence hepatocarcinogenesis. Moreover, our analysis of sequential biopsy specimens demonstrated that the progression rate of liver fibrosis significantly accelerated in patients aged  $>65$  years. Hence, the progression of fibrosis along with aging may also contribute to the increased risk for hepatocarcinogenesis in older patients.

We further demonstrated that liver steatosis was an independent risk factor for the development of HCC, which was not mentioned in previous reports.<sup>8-11</sup> The presence of steatosis is related to both viral (genotype-3 or HCV core protein) and host metabolic factors.<sup>17,18</sup> In our cohort, most superimposed NASH was associated with host metabolic factors such as high body mass index and hyperglycemia, whereas infection of genotype-3 was only noted in two patients. In vitro experiments have suggested an association between liver steatosis induced by HCV core protein and hepatocarcinogenesis,<sup>19</sup> and have proposed virus-associated steatohepatitis as a new aspect of chronic hepatitis C.<sup>20,21</sup> Because steatosis was likely to be related to hepatocarcinogenesis, patients with chronic hepatitis C, whose liver histology shows superimposed NASH,

**Table 3. Factors Associated with HCC After IFN Therapy**

Risk Factor Value	Univariate Analysis		Multivariate Analysis	
	Risk Ratio (95% CI)	P Value	Risk Ratio (95% CI)	P Value
Age (by every 10 year)	2.2 (1.8-2.7)	<0.001	3.0 (1.9-4.8)	<0.001
Sex				
Female	1		1	
Male	1.2 (0.9-1.6)	0.2	2.0 (1.0-3.8)	0.04
BMI (by every 10 kg/m <sup>2</sup> )	2.0 (1.2-1.3)	0.005	1.1 (0.4-3.5)	0.8
Fibrosis stage				
F0/F1/F2	1		1	
F3/F4	5.4 (3.9-7.5)	<0.001	2.5 (1.2-4.9)	0.01
Degree of steatosis				
<10%	1		1	
≥10%	4.5 (3.0-6.9)	<0.001	3.5 (1.9-6.4)	<0.001
Esophagogastric varices				
No	1		1	
Yes	3.3 (2.0-5.3)	<0.001	1.6 (0.6-4.4)	0.3
Virological response				
SVR	1		1	
Non-SVR	3.3 (2.1-5.2)	<0.001	2.6 (1.2-5.5)	0.001
Genotype				
Non-1	1		1	
1	1.7 (1.2-2.5)	0.006	1.0 (0.5-2.3)	0.9
Albumin (by every 1 g/dL)	0.2 (0.1-0.3)	<0.001	0.6 (0.2-2.2)	0.3
ALT (by every 100 IU/L)	1.0 (0.9-1.0)	0.8	0.4 (0.1-1.8)	0.6
AST (by every 100 IU/L)	1.2 (1.1-1.3)	0.001	1.1 (0.6-1.8)	0.8
γ-GTP (by every 100 IU/L)	1.3 (1.1-1.6)	0.009	0.6 (0.3-1.6)	0.3
ALP (by every 100 IU/L)	1.3 (1.2-1.5)	<0.001	0.6 (0.3-1.2)	0.2
Total bilirubin (by every 1 mg/dL)	1.6 (1.3-2.1)	<0.001	1.2 (0.6-2.7)	0.6
Total cholesterol (by every 100 mg/dL)	0.3 (0.2-0.6)	<0.001	0.2 (0.1-0.6)	0.006
Triglyceride (by every 100 mg/dL)	0.8 (0.5-1.1)	0.2	0.1 (0.02-1.1)	0.08
Fasting blood sugar (by every 100 mg/dL)	1.8 (1.5-2.2)	<0.001	1.1 (1.0-1.1)	0.04
WBC (by every 100/μL)	0.1 (0.03-0.3)	<0.001	0.1 (0.01-2.2)	0.2
RBC (by every 10 <sup>6</sup> /μL)	0.5 (0.4-0.7)	<0.001	1.8 (0.7-4.4)	0.2
Platelet counts (by every 10 <sup>6</sup> /μL)	0.3 (0.2-0.4)	<0.001	0.6 (0.3-1.5)	0.3
Baseline AFP (by every 10 ng/mL)	1.0 (0.9-1.1)	0.2	1.3 (1.0-1.7)	0.04
Post IFN AFP (by every 10 ng/mL)	1.2 (1.1-1.3)	<0.001	1.9 (1.5-2.4)	<0.001
HCV load (by every 100 KIU/mL)	1.0 (0.9-1.0)	0.4	1.0 (1.0-1.1)	0.06
IFN regimen				
IFN monotherapy	1		1	
IFN + RBV (24 W)	1.2 (0.8-1.8)	0.4	1.5 (0.7-3.2)	0.3
PEG-IFN monotherapy (48 W)	1.1 (0.6-1.9)	0.8	1.5 (0.4-5.5)	0.6
PEG-IFN + RBV	0.4 (0.2-0.9)	0.03	1.0 (0.3-3.1)	0.9

Risk ratios for development of HCC were calculated by Cox proportional hazards regression analysis. AFP, alpha fetoprotein; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; γ-GTP, gamma-glutamyltranspeptidase; HCC, hepatocellular carcinoma; IFN, interferon; PEG, pegylated; RBC, red blood cell counts; RBV, ribavirin; SVR, sustained virological response; WBC, white blood cell count.

may be at a higher risk of developing HCC. Further study is necessary to confirm this association in a clinical situation. Because several developed countries are in the midst of a growing obesity epidemic, the risk related to obesity cannot be ignored in patients with chronic hepatitis C who are treated with interferon.

Several retrospective cohort studies have been conducted to evaluate the effect of interferon on the incidence of HCC among patients with chronic hepatitis C.<sup>8-11</sup> Our results, obtained from one of the largest cohort studies, confirm the efficacy of viral eradication in preventing HCC. In one study conducted in a Western population, no statistically significant reduc-

tion was found in the development of HCC among patients with SVR compared with those without SVR (adjusted hazard ratio, 0.46; 95% CI, 0.12-1.70;  $P = 0.25$ ).<sup>12</sup> Because relatively few occurrences of HCC were observed in this cohort, and the duration of follow-up was shorter, the differences in HCC development between patients with and without SVR might be less pronounced.

Interestingly, our results demonstrated that the risk for HCC remains even after achieving SVR in older patients, confirming the findings of previous studies conducted with a smaller number of patients.<sup>22,23</sup> The cumulative incidence of HCC during the first 5 years

**Table 4. Factors Associated with Development of HCC After Achieving SVR**

Risk Factor	Odds Ratio (95% CI)	P-value
<b>Univariate analysis</b>		
Age (by every 10 year)	3.2 (1.8-5.5)	<0.001
Sex		
Female	1	
Male	3.0 (1.0-8.8)	0.04
Fibrosis stage		
F0/F1/F2	1	
F3/F4	5.9 (2.5-14.0)	<0.001
Degree of steatosis		
<10%	1	
≥10%	5.5 (2.0-15.2)	0.001
BMI (by every 10 kg/m <sup>2</sup> )	3.2 (0.8-12.6)	0.09
ALT (by every 10 IU/L)	0.9 (0.7-1.3)	0.7
AST (by every 10 IU/L)	1.1 (0.9-1.4)	0.3
Genotype		
Non-1	1	
1	1.2 (0.6-3.0)	0.5
HCV load (by every 100 KIU/mL)	0.9 (0.8-1.0)	0.2
IFN regimen		
IFN monotherapy	1	
IFN + RBV (24 W)	0.7 (0.2-2.3)	0.5
PEG-IFN monotherapy (48 W)	0.8 (0.2-3.6)	0.8
PEG-IFN + RBV	0.3 (0.03-2.0)	0.2
<b>Multivariate analysis</b>		
Age (by every 10 year)	2.7 (1.5-5.1)	0.002
Sex		
Female	1	
Male	4.1 (0.9-18.9)	0.06
Fibrosis stage		
F0/F1/F2	1	
F3/F4	2.6 (0.9-7.5)	0.08
Degree of steatosis		
<10%	1	
≥10%	5.6 (1.9-16.5)	0.002

Odds ratios for SVR were calculated by logistic regression analysis.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; HCV, hepatitis C virus; IFN, interferon; HCC, hepatocellular carcinoma; PEG, pegylated; RBV, ribavirin; SVR, sustained virological response.

after completion of interferon therapy was similar between SVR and non-SVR patients in the older age group, and the risk for HCC remained for 9 years after eradication of HCV in our patients. Therefore, HCC patients with SVR who have a risk factor should be screened for at least 5-10 years after the completion of interferon therapy.

It has been reported that coffee consumption has a protective effect against hepatocarcinogenesis<sup>24,25</sup> and liver disease progression in patients with chronic HCV infection.<sup>26</sup> Because we could not review coffee consumption in all the patients and fewer data were available in the previous literature as to whether a habitual change of reducing coffee consumption occurs in older patients, it is unclear whether increased risk for HCC in older patients is an effect of this habitual change in older patients. However, the majority (68%) of Japa-

nese patients who have HCV (n = 1058) drink less than 1 cup of coffee per day, and only 7.6% consume more than 3 cups of coffee per day.<sup>27</sup> Therefore, it is unlikely that a habitual change in older patients affects the increased risk for hepatocarcinogenesis in older patients.

Recently, it was reported that interferon therapy might be less effective in preventing HCC among patients with chronic hepatitis C who are positive for anti-HBc antibody,<sup>28</sup> but this finding is still controversial.<sup>29,30</sup> In the present study, anti-HBc was only detected in 4 of 22 patients in whom HCC developed after viral eradication, and age distribution was similar among anti-HBc-positive and anti-HBc-negative patients. Because no significant difference in mean age was found between anti-HBc-positive and anti-HBc-negative patients in the recent study conducted in Japan,<sup>28</sup> it is unlikely that previous exposure to hepatitis B virus or occult hepatitis B virus infection is responsible for the difference in risk for HCC between younger and elderly patients found in the present study.

In conclusion, aging has become one of the most important risk factors for HCC. Even after stratification by stage of fibrosis, the risk for HCC after antiviral treatment was significantly higher in older patients, and HCV eradication had a smaller effect on HCC-free survival in older patients. Patients with HCV should therefore be identified at an earlier age and antiviral treatment should be initiated. The present results have potentially important clinical implications for physicians that may influence their decisions about the treatment strategy in individual patients.

## References

- Parkin DM. Global cancer statistics in the year 2000. *Lancet Oncol* 2001;2:533-543.
- Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. *Semin Liver Dis* 1995;15:64-69.
- Llover JM, Burroughs A, Bruix J. Hepatocellular carcinoma. *Lancet* 2003;362:1907-1917.
- Kiyosawa K, Sodeyama T, Tanaka E, Gigo Y, Yoshizawa K, Nakano Y, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. *HEPATOLOGY* 1990;12:671-675.
- Tanaka Y, Hanada K, Mizokami M, Yao AE, Shih JW, Gojobori T, et al. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. *Proc Natl Acad Sci U S A* 2002;99:15584-15589.
- U.S. Census Bureau. Population Projections. U.S. Interim Projections by Age, Sex, Race, and Hispanic Origin: 2000-2050. <http://www.census.gov/population/www/projections/usinterimproj/>. Page last modified: September 14, 2009.
- Yancik R. Population aging and cancer: a cross-national concern. *Cancer J* 2005;11:437-441.

8. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. *Ann Intern Med* 1998;129:94-99.
9. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. *HEPATOLOGY* 1999;29:1124-1130.
10. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. *Ann Intern Med* 1999;131:174-181.
11. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. *HEPATOLOGY* 2007;45:579-587.
12. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. *Ann Intern Med* 2007;147:677-684.
13. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. *HEPATOLOGY* 1994;19:1513-1520.
14. Hamada H, Yatsunami H, Yano K, Daikoku M, Arisawa K, Inoue O, et al. Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C. *Cancer* 2002;95:331-339.
15. Ohishi W, Kitamoto M, Aikata H, Kamada K, Kawakami Y, Ishihara H, et al. Impact of aging on the development of hepatocellular carcinoma in patients with hepatitis C virus infection in Japan. *Scand J Gastroenterol* 2003;38:894-900.
16. Miki D, Aikata H, Uka K, Saneto H, Kawaoka T, Azakami T, et al. Clinicopathological features of elderly patients with hepatitis C virus-related hepatocellular carcinoma. *J Gastroenterol* 2008;43:550-557.
17. Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. *HEPATOLOGY* 2002;36:1266-1272.
18. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. *HEPATOLOGY* 2002;36:729-736.
19. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. *Nat Med* 1998;4:1065-1067.
20. Koike K, Moriya K. Metabolic aspects of hepatitis C viral infection: steatohepatitis resembling but distinct from NASH. *J Gastroenterol* 2005;40:329-336.
21. Koike K, Moriya K, Matsuura Y. Animal models for hepatitis C and related liver disease. *Hepatol Res* 2010;40:69-83.
22. Tokita H, Fukui H, Tanaka A, Kamitsukasa H, Yagura M, Harada H, et al. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy. *J Gastroenterol Hepatol* 2005;20:752-758.
23. Toyoda H, Kumada T, Tokuda A, Horiguchi Y, Nakano H, Honda T, et al. Yon-Ken HCV-HCC Follow-up Study Group. Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C. *J Viral Hepat* 2000;7:414-419.
24. Larsson SC, Wolk A. Coffee consumption and risk of liver cancer: a metaanalysis. *Gastroenterology* 2007;132:1740-1745.
25. Bravi F, Bosetti C, Tavani A, Bagnardi V, Gallus S, Negri E, et al. Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. *HEPATOLOGY* 2007;46:430-435.
26. Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, et al. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. *HEPATOLOGY* 2009;50:1360-1369.
27. Inoue M, Kurahashi N, Iwasaki M, Shimazu T, Tanaka Y, Mizokami M, et al. Effect of coffee and green tea consumption on the risk of liver cancer: cohort analysis by hepatitis virus infection status. *Cancer Epidemiol Biomarkers Prev* 2009;18:1746-1753.
28. Ikeda K, Marusawa H, Osaki Y, Nakamura T, Kitajima N, Yamashita Y, et al. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. *Ann Intern Med* 2007;146:649-656.
29. Stroffolini T, Almasio PL, Persico M, Bollani S, Benvegnù L, Di Costanzo G, et al. Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis. *Am J Gastroenterol* 2008;103:1966-1972.
30. Hiraoka T, Katayama K, Tanaka J, Ohno N, Joko K, Komiya Y, et al. Lack of epidemiological evidence for a role of resolved hepatitis B virus infection in hepatocarcinogenesis in patients infected with hepatitis C virus in Japan. *Intervirology* 2003;46:171-176.

## Review Article

# Predictors of Virological Response to a Combination Therapy with Pegylated Interferon Plus Ribavirin Including Virus and Host Factors

Namiki Izumi, Yasuhiro Asahina, and Masayuki Kurosaki

*Department of Gastroenterology and Hepatology, Musashino Red-Cross Hospital, Kyonancho 1-26-1, Musashinoshi, 180-8610 Tokyo, Japan*

Correspondence should be addressed to Namiki Izumi, nizumi@musashino.jrc.or.jp

Received 25 April 2010; Revised 29 June 2010; Accepted 19 July 2010

Academic Editor: Ming-Lung Yu

Copyright © 2010 Namiki Izumi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A combination therapy with pegylated interferon (PEG-IFN) plus ribavirin (RBV) has made it possible to achieve a sustained virological response (SVR) of 50% in refractory cases with genotype 1b and high levels of plasma HCVRNA. Several factors including virus mutation and host factors such as age, gender, fibrosis of the liver, lipid metabolism, innate immunity, and single nucleotide polymorphism (SNPs) are reported to be correlated to therapeutic effects. However, it is difficult to determine which factor is the most important predictor for an individual patient. Data mining analysis is useful for combining all these together to predict the therapeutic effects. It is important to analyze blood tests and to predict therapeutic effects prior to initiating treatment. Since new anti-HCV agents are under development, it will be necessary in the future to select the patients who have a high possibility of achieving SVR if treatment is performed with standard regimen.

## 1. Progress in Virological Response in the Difficult-to-Treat Patients with Genotype 1 Hepatitis C Virus (HCV) Infection and Factors Correlated to the Efficacy

Recently, the average age of the patients with chronic hepatitis C has been increasing in Japan. Incidence of hepatocellular carcinoma (HCC) in the elderly patients with chronic hepatitis C (65 years or older) has demonstrated to be higher than younger ones when adjusted by the stage of hepatic fibrosis [1]. In Japan, refractory cases with genotype 1b and high HCVRNA levels are seen in as high as 70 percent of chronic hepatitis C patients. The outcome of conventional IFN monotherapy has been an SVR response of 3%–5% after 6 months of treatment in genotype 1b and high HCVRNA patients [2, 3], and virus mutation such as interferon sensitivity-determining region (ISDR) is shown to be correlated with the virological response [2]. The association of ISDR mutations and virological response to IFN monotherapy was denied in an Italian study [4];

however, it was confirmed by a Chinese study [5] and an international meta-analysis [6].

However, pegylated IFN (PEG-IFN) extends the duration of therapy and reduces adverse effects, and for this reason, PEG-IFN has become the cornerstone of therapy. Furthermore, by the combination therapy with PEG-IFN and ribavirin (RBV), the rate of SVR has dramatically improved. Even in the patients with genotype 1b and high HCVRNA level, SVR rate reaches as high as 40%–50%, thereby improving the therapeutic effects both in Western countries [7, 8] and in Japan [9, 10].

It is important to predict the rate of achieving SVR in the individual patient, before initiating treatment. Both virus- and host-related elements have been reported as factors correlated to therapeutic effects of combination therapy [11–13]. A particular focus has been placed on virus mutations, age, gender, fibrosis of the liver, lipid metabolism, and degree of fatty metamorphosis of the liver.

Among these factors related to PEG-IFN and RBV, innate immunity has been shown to be correlated in virological




FIGURE 1: Expression of genes correlated to the intrahepatic innate immunity and virological response to PEG-IFN alpha-2b and RBV combination therapy. Open column indicates SVR ( $n = 30$ ), gray column indicates TR ( $n = 24$ ), and closed column indicates NVR ( $n = 20$ ). Error bars indicate the standard error. The  $P$  values were analyzed by the Kruskal-Wallis test. Expression of Rig-I was significantly higher in NVR than in SVR patients, and Cardif expression was higher in SVR than in NVR. The figure was cited from [8].

response. Asahina et al. reported that liver biopsies were performed before the PEG-IFN and RBV combination therapy to examine the correlation between the gene expression involved in innate immunity and the therapeutic effects, and in the patients in whom RIG-I expression is high and the expression of Cardif, an adaptor gene, is low, it was found that there are many nonresponders (NVRs) in which HCVRNA does not become negative during the course of treatment [13]. It was therefore revealed that there are many NVRs among the patients in whom the ratio of RIG-I to Cardif in liver tissue is high and that this ratio is low in the SVR patients. Based on these findings, it has become clear that innate immunity is correlated to therapeutic effects (Figure 1).

Furthermore, it was recently discovered that a single nucleotide polymorphism (SNP) of the host gene IL28B is significantly involved in the therapeutic response to the PEG-IFN and RBV combination therapy [14, 15]. The possibility of becoming an NVR is high in cases of the minor allele carriers of IL28B. However, it is not possible to routinely measure an SNP of IL28B in the clinical setting. In this paper, factors which can actually be used in real clinical practice are discussed for the prediction of the efficacy of PEG-IFN and RBV combination therapy.

## 2. Amount of HCVRNA

In the patients with chronic hepatitis C, it is not possible to directly measure the amount of virus, and the

amount of HCVRNA is measured instead. Currently, a real-time PCR method which has an advantage of wide range and high sensitivity is utilized, and measurements can be taken from a single blood sample of a very small amount, that is, 1.2 log copies/ml, to a very large amount, that is, 8 log copies/ml. This method has a higher level of sensitivity than the conventional Amplicor monitor test and can therefore detect HCVRNA even if only a very small amount exists in the plasma. If the amount of HCVRNA in plasma is less than the range of sensitivity of the real-time PCR method, it is recorded as undetectable level. If the indication is "less than 1.2 log copies/ml of HCVRNA", it means that a very small amount of HCVRNA exists in the plasma. Since the indication of the real-time PCR method is based on log counts, a decrease of 1.0 in the numerical value means that the amount of HCVRNA has decreased to 1/10. With the application of this real-time PCR method, it has become possible to measure amounts of HCVRNA up to 8 log copies/ml, and it has also become possible to predict the efficacy before treatment and to monitor appropriately the reactivity during the course of treatment. However, in the patients in whom a PEG-IFN and RBV combination therapy is performed, SVR can be acquired even when the amount of virus prior to the treatment is quite large. It is therefore difficult to predict the virological response solely from the amount of HCVRNA before starting the treatment. Once treatment has commenced, at what week HCVRNA becomes negative is important for the prediction of therapeutic effects, and this serves as a parameter for deciding the duration of treatment [16].




FIGURE 2: Comparison of aa70 mutations in the HCV core region and the rate of HCV-RNA becoming negative during the course of treatment. Compared with the wild type, among the patients of aa70 mutations, there were fewer patients in whom HCV-RNA had become negative during the course of treatment.

Measuring the rate of viral clearance from serum is helpful for predicting the likelihood of a response to PEGIFN and RBV and useful for determining the optimal duration of therapy if the patients start to receive the treatment [17]. In the AASLD practice guideline, response-guided therapy is highly recommended [18]. In two nationwide registration trials conducted in Japan [9, 10], the SVR rate was high, from 76% to 100%, in patients whose HCV-RNA was cleared rapidly from serum by week 4 (rapid virological response; RVR), and 71% to 73% in patients who achieved undetectable HCV-RNA from week 5 to week 12 (early virological response; EVR). In contrast, the SVR rate in patients with late clearance of HCV-RNA from week 13 to week 24 was low at 29% to 36%. No patients without clearance of HCV-RNA by week 24 achieved SVR.

The strategy of extending therapy in patients with delayed virological responses, defined as clearance of HCV-RNA between weeks 12 and 24, was evaluated in five studies [19–23]. These results cannot be compared directly with each other because of the heterogeneous study populations, differences in the baseline characteristics, and the different regimens utilized amongst them. Nevertheless, the results showed a trend toward a higher SVR rate by extending therapy from 48 to 72 weeks in patients with delayed virological response.

### 3. Viral Mutations in Core and NS5A Region

In the patients with genotype 1b HCV infection, the mutations in aa70 and aa91 in the core region have been shown to correlate with early virological response (EVR) during PEG-IFN and RBV combination treatment [11]. If aa70 in the core region is mutated to anything other than arginine and aa91 to anything other than leucine, it is difficult to achieve EVR, and it is thus highly possible that such cases




FIGURE 3: Number of ISDR substitutions and the comparison of virological response, SVR, and relapse at the end of the treatment. Compared with the patients with 2 or more sites of substitutions, the rate of SVR was lower and the rate of relapse was higher in the patients in whom there were fewer substitutions in ISDR, that is, 0 or 1 sites.

will become nonresponders. The examination results at our institution including 292 patients with genotype 1b infection demonstrated that, in the cases with mutations in aa70 in the core region, the rate of HCV-RNA becoming negative during the course of combination treatment was low compared to the wild type of aa70 (Figure 2). However, core aa70 mutation is shown to have quasispecies detectable by cloning, and 70Q clone was positively selected during combination treatment with PEGIFN and RBV [24].

Furthermore, Enomoto et al. reported that the patients with 4 or more amino acid mutations were observed in interferon sensitivity-determining region (ISDR) within NS5A region [2]; SVR rate is higher than 90% by IFN monotherapy, and SVR is less than 10% in the patients with no mutation in ISDR. It has also been reported that, in PEG-IFN and RBV combination therapy, the number of ISDR mutations is involved in the SVR [12].

We analyzed the relationship between virological response and ISDR mutations in the patients with genotype 1b infection treated by PEG-IFN alpha-2b and BRV combination therapy. In the patients with 0 or 1 ISDR mutation, even if the rate of HCV-RNA becoming negative at the end of treatment was the same, the rate of SVR would be lower compared with the patients having 2 or more mutations (Figure 3). This demonstrates that there is a higher incidence of relapse after the end of treatment in the patients with 0 or 1 ISDR mutation.

Enomoto and Maekawa reported that mutations both in NS5A-ISDR (interferon sensitivity-determining region) and core 70Q substitution are associated with no early viral response during PEGIFN and RBV combination therapy [25]. Association of core aa70 substitution and mutations in NS5A region is confirmed to be associated with viral response by PEGIFN and RBV combination therapy in a Japanese multicenter cooperative study [26]. The number of



mutations in the interferon sensitivity-determining region was shown to be associated with the viral response to PEGIFN and RBV combination treatment not only in Japan [27], but also in Tunisia [28].

Recently, a consensus has been established that mutations in aa70 in the core region are important for the prediction of HCVRNA becoming negative during the early course of treatment, and the number of ISDR mutations is important for the prediction of relapse after the end of treatment.

#### 4. Adherence

It has been confirmed that it is important to ensure 80% or more of the scheduled dose of both PEG-IFN and RBV in order to improve the rate of SVR, and together with the duration of treatment, the 80 · 80 · 80 rule has been established. However, Schiffman et al. recently reported that the dose of PEG-IFN in the initial stage of administration is important and that, if a sufficient dose of PEG-IFN is administered, then 60% or more of the RBV dose would be enough [29]. It is therefore of primary importance to ensure the dose of PEG-IFN.

In Japan, the average age of patients with chronic hepatitis C is increasing, and achieving good adherence is difficult in many patients. Consequently, the rate of SVR is low in elderly patients. How to improve the rate of SVR in elderly patients is an important issue. With regard to the dose of RBV, reducing the RBV dose based on the calculation of the total body clearance (CL/F) has been proposed to be useful for decreasing the discontinuation and improving the rate of SVR. Although there is no consensus on an appropriate dose of PEG-IFN in elderly patients, if the initial dose is set lower than the usual dose, discontinuation would be reduced. Thus, it is necessary to investigate whether such an initial dose would improve the rate of SVR.

Recently, the risk of hemolytic anemia was clearly demonstrated to correlate with ITAP gene SNP [30]. The predictive implication should be analyzed prospectively in clinical practice.

#### 5. Host Factors

Zeuzem et al. described the factors related to the less response to interferon-based therapy, and he showed that several host factors such as older age, race, and obesity are responsible factors for the poor response to IFN [31]. Recently, insulin resistance which was examined by homeostasis model assessment index (HOMA-IR) was shown to be associated with a lower rate of SVR, and body mass index (BMI) was not identified as a significant factor for the poor response to PEGIFN and ribavirin combination therapy [32]. Insulin resistance was confirmed as a related factor to the nonresponse to interferon-based treatment [33]. However, Charlton et al. reported that obesity itself is an associated factor for decreased efficacy of interferon-based therapies, and they discussed the possible mechanism [34], and obesity was shown to be associated with the increased enhancement

of suppressor of cytokine signaling (SOCS) family in the hepatocytes [35].

#### 6. Data Mining Analysis

Both virus- and host-related factors are correlated to therapeutic effects of PEG-IFN and RBV. One important question is which of these factors should be focused on in order to predict the therapeutic effects in an individual patient. In addition, in each individual patient, the host and virological factors are different. It is therefore difficult to predict the virological response in each case before treatment. Furthermore, although it is important to predict the relapse rate when HCVRNA becomes within an undetectable level in an individual patient, prediction of the rate of SVR including virological and host factors and adherence to the treatment has never been carried out in an individual patient.

A data mining analysis is the process of analyzing a large amount of data by a computer in order to develop an algorithm. Conventional statistics have been used to examine certain hypothesis. Data mining is superior in that it can set an algorithm, using a computer, based on a large amount of data without a hypothesis.

We therefore conducted at our institute a data mining analysis of the patients with genotype 1b infection having high levels of HCVRNA to whom a PEG-IFN alpha-2b and RBV combination therapy was administered to investigate whether by the 12th week after the commencement of treatment HCVRNA became negative (EVR) (Figure 4) [36]. The most important factor for the prediction of EVR was the steatosis of the liver: when steatosis was observed in 30% or more of hepatocytes, EVR was found to be difficult to achieve. In the patients in whom steatosis was not severe, the second most important factor was the serum LDL cholesterol value. While the rate of EVR was 57% in the patients in whom this value was 100 mg/ml or above, the rate of EVR was 32% in the patients in whom the LDL cholesterol was less than 100 mg/dl.

The higher the LDL cholesterol value, the earlier the HCVRNA became negative. Among the patients with low LDL cholesterol values, while the rate of EVR was 15% in patients 60 years of age or older, the rate was high in the patients under the age of 60 years old, that is, 49%. Among patients under the age of 60, the rate of EVR was low, that is, 31%, in patients with a blood glucose level of 120 mg/dl or above whereas EVR was achieved in 71% of the patients with a blood glucose level of less than 120 mg/dl (Figure 4).

On the other hand, in the patients with high LDL cholesterol values, the next most important factor was age. While the rate of EVR was 50% in patients 50 years of age or older, EVR was achieved in 77% of the patients under the age of 50. Among patients of 50 years of age or older, the next most important factor was the gamma GTP value. While the rate of EVR was 35% in the patients in whom gamma GTP was 40 IU/L or above, EVR was achieved in 60% of the patients where the value was less than 40 IU/L.




FIGURE 4: HCV RNA negative (EVR) algorithm at 12th week from data mining analysis of PEG-IFN alpha-2b plus RBV combination in the genotype 1b and high levels of HCV RNA. Both virological and host factors were evaluated by data mining analysis software from SPSS. This figure was cited from [36].




FIGURE 5: The rate of EVR in the patients with genotype 1b and high levels of HCV RNA, based on fatty deposition in the liver (a), and the LDL cholesterol value (b), respectively. EVR was highly achieved in the patients with less steatosis in the liver, and in those with high serum LDL-cholesterol levels. This is univariate analysis, and cited from [36].

We therefore compared these factors based on the original data. A univariate comparison of the fatty infiltration of the liver and the rate of EVR demonstrated that the rate of EVR was higher when the steatosis of the liver was less severe (Figure 5(a)). In addition, a comparison of the LDL cholesterol value and the rate of EVR demonstrated a significant correlation, confirming that the higher the LDL cholesterol value, the higher the rate of EVR (Figure 5(b)). Therefore, it was also proposed by the results of univariate analysis of each factor extracted from the data mining analysis that these factors were correlated to the rate of EVR.

From these observations, it is likely to improve the viral response to PEGIFN and ribavirin by reducing steatosis of the liver through daily walking or abstaining alcohol intake or by refraining from high-fat diet.

By utilizing data mining, it is therefore possible to assess virus- and host-related factors together and to predict the virological response in each patient, and thereby clinically useful information can be obtained. The algorithm should be validated including a large number of the patients.

## Acknowledgment

This paper was supported by a grant from the Japanese Ministry of Health, Welfare and Labor.

## References

- [1] Y. Asahina, K. Tsuchiya, I. Hirayama, et al., "Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection," *Hepatology*, vol. 52, no. 2, pp. 518–527, 2010.
- [2] N. Enomoto, I. Sakuma, Y. Asahina et al., "Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection," *New England Journal of Medicine*, vol. 334, no. 2, pp. 77–81, 1996.
- [3] S. Iino, F. Ichida, A. Sakuma et al., "A randomized clinical trial with natural interferon- $\alpha$  monotherapy for 24 or 48 weeks on patients with chronic hepatitis C having genotype 1b infection in high viral titers," *Hepatology Research*, vol. 24, no. 4, pp. 338–345, 2002.
- [4] G. Squadrito, M. E. Orlando, I. Cacciola et al., "Long-term response to interferon alpha is unrelated to "interferon sensitivity determining region" variability in patients with chronic hepatitis C virus-1b infection," *Journal of Hepatology*, vol. 30, no. 6, pp. 1023–1027, 1999.
- [5] C. Shen, T. Hu, L. Shen, L. Gao, W. Xie, and J. Zhang, "Mutations in ISDR of NS5A gene influence interferon efficacy in Chinese patients with chronic hepatitis C virus genotype 1b infection," *Journal of Gastroenterology and Hepatology*, vol. 22, no. 11, pp. 1898–1903, 2007.
- [6] M. Pascu, P. Martus, M. Hühne et al., "Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences," *Gut*, vol. 53, no. 9, pp. 1345–1351, 2004.
- [7] S. J. Hadziyannis, H. Sette Jr., T. R. Morgan et al., "Peginterferon- $\alpha$ 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose," *Annals of Internal Medicine*, vol. 140, no. 5, pp. 346–355, 2004.
- [8] M. P. Manns, J. G. McHutchison, S. C. Gordon et al., "Peginterferon alfa-2b plus ribavirin compared with interferon- $\alpha$ 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial," *Lancet*, vol. 358, no. 9286, pp. 958–965, 2001.
- [9] S. Iino, E. Tomita, H. Kumada et al., "Prediction of treatment outcome with daily high-dose IFN  $\alpha$ -2b plus ribavirin in patients with chronic hepatitis C with genotype 1b and high HCV RNA levels: relationship of baseline viral levels and viral dynamics during and after therapy," *Hepatology Research*, vol. 30, no. 2, pp. 63–70, 2004.
- [10] G. Yamada, S. Iino, T. Okuno et al., "Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon- $\alpha$ -2a plus ribavirin dose reductions and host-related factors," *Clinical Drug Investigation*, vol. 28, no. 1, pp. 9–16, 2008.
- [11] N. Akuta, F. Suzuki, Y. Kawamura et al., "Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels," *Journal of Hepatology*, vol. 46, no. 3, pp. 403–410, 2007.
- [12] H. Shirakawa, A. Matsumoto, S. Joshita et al., "Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors," *Hepatology*, vol. 48, no. 6, pp. 1753–1760, 2008.
- [13] Y. Asahina, N. Izumi, I. Hirayama et al., "Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response," *Gastroenterology*, vol. 134, no. 5, pp. 1396–1405, 2008.
- [14] D. Ge, J. Fellay, A. J. Thompson et al., "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance," *Nature*, vol. 461, no. 7262, pp. 399–401, 2009.
- [15] Y. Tanaka, N. Nishida, M. Sugiyama et al., "Genome-wide association of IL28B with response to pegylated interferon- $\alpha$  and ribavirin therapy for chronic hepatitis C," *Nature Genetics*, vol. 41, no. 10, pp. 1105–1109, 2009.
- [16] P. Ferenci, H. Laferl, T. Scherzer et al., "Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response," *Gastroenterology*, vol. 135, no. 2, pp. 451–458, 2008.
- [17] N. Izumi, S. Nishiguchi, K. Hino et al., "Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009)," *Hepatology Research*, vol. 40, no. 4, pp. 347–368, 2010.
- [18] M. G. Ghany, D. B. Strader, D. L. Thomas, and L. B. Seeff, "Diagnosis, management, and treatment of hepatitis C: an update," *Hepatology*, vol. 49, no. 4, pp. 1335–1374, 2009.
- [19] T. Berg, M. von Wagner, S. Nasser et al., "Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon- $\alpha$ -2a plus ribavirin," *Gastroenterology*, vol. 130, no. 4, pp. 1086–1097, 2006.
- [20] J. M. Sánchez-Tapias, M. Diago, P. Escartín et al., "Peginterferon- $\alpha$ 2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment," *Gastroenterology*, vol. 131, no. 2, pp. 451–460, 2006.
- [21] P. Ferenci, H. Laferl, T. M. Scherzer, et al., "Customizing treatment with peginterferon alfa-2a (40kD)(PEGASYS®) plus ribavirin (COPEGUS®) in patient with HCV genotype 1 or 4 infection: interim results of a prospective randomized trial," *Hepatology*, vol. 44, no. 336a, 2006.
- [22] B. L. Pearlman, C. Ehleben, and S. Saifee, "Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C

- genotype 1-infected slow responders," *Hepatology*, vol. 46, no. 6, pp. 1688–1694, 2007.
- [23] M. Buti, Y. Lurie, N. G. Zakharova, et al., "Extended treatment duration in chronic hepatitis C genotype 1-infected slow responders: final results of the SUCCEED study," *Journal of Hepatology*, vol. 50, supplement 1, p. S58, abstract 141, 2009.
- [24] F. Kurbanov, Y. Tanaka, K. Matsuura et al., "Positive selection of core 70Q variant genotype 1b hepatitis C virus strains induced by pegylated interferon and ribavirin," *Journal of Infectious Diseases*, vol. 201, no. 11, pp. 1663–1671, 2010.
- [25] N. Enomoto and S. Maekawa, "HCV genetic elements determining the early response to peginterferon and ribavirin therapy," *Intervirology*, vol. 53, no. 1, pp. 66–69, 2010.
- [26] T. Okanou, Y. Itoh, H. Hashimoto et al., "Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study," *Journal of Gastroenterology*, vol. 44, no. 9, pp. 952–963, 2009.
- [27] M. Nakagawa, N. Sakamoto, M. Ueyama et al., "Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection," *Journal of Gastroenterology*, vol. 45, no. 6, pp. 656–665, 2010.
- [28] N. Bouzgarrou, E. Hassen, W. Mahfoudh et al., "NS5AISDR-V3 region genetic variability of Tunisian HCV-1b strains: correlation with the response to the combined interferon/ribavirin therapy," *Journal of Medical Virology*, vol. 81, no. 12, pp. 2021–2028, 2009.
- [29] M. L. Shiffman, M. G. Ghany, T. R. Morgan et al., "Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C," *Gastroenterology*, vol. 132, no. 1, pp. 103–112, 2007.
- [30] J. Fellay, A. J. Thompson, D. Ge et al., "ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C," *Nature*, vol. 464, no. 7287, pp. 405–408, 2010.
- [31] S. Zeuzem, "Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?" *Annals of Internal Medicine*, vol. 140, no. 5, pp. 370–381, 2004.
- [32] H. S. Conjeevaram, D. E. Kleiner, J. E. Everhart et al., "Race, insulin resistance and hepatic steatosis in chronic hepatitis C," *Hepatology*, vol. 45, no. 1, pp. 80–87, 2007.
- [33] G. Tarantino, P. Conca, P. Sorrentino, and M. Ariello, "Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis," *Journal of Gastroenterology and Hepatology*, vol. 21, no. 8, pp. 1266–1268, 2006.
- [34] M. R. Charlton, P. J. Pockros, and S. A. Harrison, "Impact of obesity on treatment of chronic hepatitis C," *Hepatology*, vol. 43, no. 6, pp. 1177–1186, 2006.
- [35] M. J. Walsh, J. R. Jonsson, M. M. Richardson et al., "Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signaling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1," *Gut*, vol. 55, no. 4, pp. 529–535, 2006.
- [36] M. Kurosaki, K. Matsunaga, I. Hirayama, et al., "A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis," *Hepatology Research*, vol. 40, no. 3, pp. 251–260, 2010.